After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after a year of muscular performance and its recent and massive deal with Takeda Pharmaceutical Co. Ltd. Read More

News that Trevi Therapeutics Inc. got the size just right of the phase IIb Coral trial with Haduvio (oral nalbuphine extended release) led the company’s shares (NASDAQ:TRVI) to close Dec. 12 at $3.60, up $1.11, or 45%, after trading as high as $4.60. Read More

By the end of November 2024, the BioWorld Neurological Diseases Index had dropped 13.4%, deepening its decline of 9.4% at the end of August. Meanwhile, the Dow Jones Industrial Average surged 19.16% in the first 11 months of the year, building on a 10.81% gain reported at the end of October. The Nasdaq Biotechnology Index posted a year-to-date increase of 6.27% through November, retreating from its peak gain of 11.7% in August. Read More

Caliway Biopharmaceuticals’ lipolysis candidate, CBL-514, met all the primary and secondary efficacy endpoints in a phase IIb study for subcutaneous fat reduction, paving the way for the company to begin a global pivotal phase III study in 2025. Read More

SK Bioscience Co. Ltd. gained approval from the Human Research Ethics Committee in Australia to start phase I/II trials of GBP-560, its mRNA-based vaccine candidate for mosquito-borne Japanese encephalitis virus, with funding from Coalition for Epidemic Preparedness Innovations. Read More

New hires and promotions in the biopharma industry, including: Cosmo, Invea, Zentalis. Read More

Biopharmas raising money in public or private financings, including: Ambrosia, Angitia, Biovaxys, Cellectis, Chroma Medicine, Immunitybio, Merck, Nchroma, Nvelop, Okogen, Tasca, Veradermics. Read More

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acelyrin, ADC, Anaptysbio, Arrowhead, Astria, Candel, Dizal, Ionctura, Minoryx, Moberg, Pharming, Q32, Horizon, Scilex, Siga, Sound, Spruce. Read More

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Aliada, Asahi Kasei, Bayer, Biopath Holdings, Cellactar, Chiome, Hepion, Hong Kong King-Friend Industrial, Immunogenesis, Meitheal, Moberg, Monte Rosa, Novartis, Negev Labs, Pharma Two B, Phathom, Polypid, VBI Vaccines. Read More

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cipla, Mannkind, Pilatus, Sanofi, Santhera, Theratechnologies. Read More